Repression of the memory suppressor gene histone deacetylase 2 (Hdac2) in mice elicits cognitive enhancement, and drugs that block HDAC2 catalytic activity are being investigated for treating disorders affecting memory.
INTRODUCTION
Long-term memory formation and retention requires coordinated transcriptional changes that are regulated by modifications to the epigenome. Decreasing acetylation by inhibiting histone acetyltransferases (HATs) such as CREB-binding protein (CBP) impairs long-term memory (Alarcon et al. 2004; Korzus et al. 2004; Wood et al. 2005) , while increasing acetylation by inhibiting histone deacetylases (HDACs) enhances longterm memory (Levenson et al. 2004; Hawk et al. 2011) . Eleven isoforms of classical HDAC proteins exist in mammals, and evidence suggests HDAC2 in particular is responsible for regulating synaptic plasticity and memory formation relative to its close homolog HDAC1 and other HDAC isoforms (Guan et al. 2009 ). Knockout of the Hdac2 gene in mice improves hippocampal and prefrontal-cortex dependent learning tasks (Guan et al. 2009 ; Morris et al. 2013) . Specific inhibition of HDAC2 has been a goal of pharmacological design (Wang et al. 2005 ; Choubey and Jeyakanthan 2018), but a completely selective inhibitor of HDAC2 catalytic activity has remained elusive because of poor pharmacokinetics and promiscuous subtype selectivity.
Antisense oligonucleotides (ASOs) are clinically useful for treating a variety of diseases (Stein and Castanotto 2017) . They employ base pairing with a target messenger RNA (mRNA) to achieve selectivity. Therefore, we previously designed and tested an ASO targeting Hdac2 mRNA. This Hdac2 ASO elicited substantial memory enhancement in wild-type mice in object location memory tests, and it rescued impaired memory in a mouse model of autism (Kennedy et al. 2016) . ASOs targeting other mRNAs reduce expression of their target genes in the central nervous system (Southwell et al. 2014) for months after the last delivery of the drug (Kordasiewicz et al. 2012; Meng et al. 2015a ). Because of potential therapeutic utility of the Hdac2 ASO, we wanted to determine the longevity of its Hdac2 mRNA reduction and the duration of the elicited cognitive enhancement.
The two most commonly utilized mechanisms for ASOs in therapeutic applications are 1) recruitment of RNaseH1 to the RNA/ASO hybrid and subsequent degradation of the RNA (Wu et al. 2004a) , and 2) correction of splicing defects that lead to disease when the ASO is designed to target splice junctions (Sazani et al. 2002; Alter et al. 2006) . Because ASOs can modulate splicing, which occurs cotranscriptionally during the synthesis of RNA (Beyer et al. 1981; Osheim et al. 1985; Wu et al. 1991; Merkhofer et al. 2014) , we reasoned ASOs could 5 possibly interfere with transcription itself. Therefore, we examined more closely whether ASOs only mediate RNA degradation or might also be involved in preventing their transcriptional synthesis.
We report here that our Hdac2-targeting ASO is long-lasting and specific. A single injection of Hdac2targeted ASO in vivo reduced Hdac2 mRNA for at least 4 months, and increased memory for 8 weeks. It has high selectivity for Hdac2, but not other related histone deacetylase isoforms. Furthermore, it affects the expression levels of hundreds of genes in the brain. These genes are involved in extracellular signal-regulated kinase (ERK) signaling, memory-associated "immune" functions, synapse formation, and the regulation of flavonoids. Although the Hdac2 ASO used herein was designed to mediate degradation of target mRNA, we also found that the ASO elicits repression of an Hdac2 regulatory RNA, and stimulates transcriptional suppression of its target gene by blocking RNA polymerase II (RNA Pol II) elongation.
RESULTS

Long-term target knockdown and behavioral memory enhancement in vivo
Phosphorothiate and 2´-MOE modified ASOs have been shown to elicit prolonged RNA knockdown in the brain (Wu et al. 2004b; Kordasiewicz et al. 2012; Meng et al. 2015b) . We wanted to test the longevity of an Hdac2-targeting ASO previously shown to achieve potent knockdown (Kennedy et al. 2016) , we are calling here Hdac2 ASO1. A structurally similar scrambled (SCR) ASO that targets no known mouse genes was used as a control. We did a single intracerebroventricular (ICV) injection of SCR ASO or Hdac2 ASO1 in mice, and examined molecular and behavioral changes out to 40 weeks post-surgery (Fig. 1A) . The targeting ASO significantly reduces Hdac2 mRNA in the cortex for 32 weeks after a single Hdac2 ASO1 injection ( Fig. 1B ).
HDAC2 protein was significantly lower in the Hdac2 ASO1 group compared to the scrambled group in cortex from 3 days to 16 weeks after treatment (Fig. 1C ). The injection also elicits repression of Hdac2 mRNA level ( Fig. 1D ) and HDAC2 protein expression ( Fig. 1E ) in the hippocampus at 2, 8, and 16 weeks after injection.
The liver, which is one of the primary peripheral sites of ASO accumulation (Geary et al. 2015) , showed no significant mRNA or protein reduction at the two time points tested (2 and 32 weeks) after ICV injection 6 7 (Supplemental Fig. S1A ). Perhaps because of its anatomical distance from the cerebral ventricles, the cerebellum RNA-seq analysis revealed milder, yet significant, knockdown. In the cerebellum, the mRNA knockdown was above 50% and it was statistically significant between 2 and 16 weeks after ICV, However, protein analysis showed no significant downregulation of protein levels at 2 and 32 weeks (Supplemental Fig. S1B ).
Blocking HDAC2 has been shown to enhance memory formation, so we tested the duration of spatial memory enhancement in the ICV-injected mice. We used an object location memory (OLM) assessment of the treated animals at weeks 2, 8 and 16. Briefly, the OLM assessment is based on the spontaneous tendency of rodents to spend more time exploring an object that has been relocated. A higher discrimination index indicates that the mouse remembers the familiar placement. Animals that received a single ICV injection of Hdac2 ASO1 had a higher discrimination index compared to mice that received the control SCR ASO, with statistically significant effects at weeks 2 and 8 and a trend at 16 weeks ( Fig. 1F ).
Hdac2 ASO1 does not cross the brood-brain barrier Previous reports show that ASOs do not cross the blood-brain barrier (Cossum et al. 1993; Smith et al. 2006 ), and we wanted to test this for Hdac2 ASO1. Consistent with prior studies, injection of Hdac2 ASO1 into the tail vein did not repress Hdac2 mRNA in the brain. We do see knockdown in the liver at 2 weeks in these intravenously injected animals (Supplemental Fig. S1C ).
Isoform specificity of Hdac2-targeted ASOs
Using the RNA-seq data, we examined the isoform specificity of the Hdac2 ASO in vivo across the longitudinal study. Of the 11 isoforms of classical HDACs, the Hdac2 gene was the only isoform significantly changed at any time during the 40 weeks of the study in the cortex, hippocampus ( Fig. 2A ), and cerebellum (Supplemental Fig. S1D ).
Brain tissue contains a variety of cell types, and since the cognitive enhancement functions of Hdac2 have been ascribed predominantly to gene regulation in neurons (Guan et al. 2009; Penney and Tsai 2014) , we next tested for specific and long-lasting ASO-directed Hdac2 knockdown in neurons. We further wanted to see if our findings are unique to ASO1 or generalizable to another ASO targeting Hdac2 mRNA at a different site, so we applied Hdac2 ASO2 alongside ASO1 in mouse primary neuronal culture. ASO1 targets the 3' untranslated 8 9 region (UTR), and ASO2 targets exon 10 of the Hdac2 mRNA. Both Hdac2 ASOs lead to Hdac2 mRNA knockdown in neurons after a week of treatment relative to SCR ASO control measured by reverse transcription followed by quantitative PCR (RT-qPCR, Fig. 2B ). Furthermore, the two Hdac2 ASOs show no suppression of closely related Hdac1 mRNA (Fig. 2C) , validating their isoform specificity in neurons. Actually, Hdac1 was mildly increased in expression, which may be indicative of a compensatory mechanism (El-Brolosy and Stainier 2017). Additionally, we confirmed the efficacy and specificity of the Hdac2 ASOs in a mouse neuroblastoma Neuro2a (N2a) cell line differentiated with serum-starvation conditions (dN2a, Supplemental Fig. S2A ). The
Hdac2 ASOs likewise reduce Hdac2 (Supplemental Fig. S2B ), but not Hdac1 mRNA in this culture system (Supplemental Fig. S2C ). To test if repression of Hdac2 mRNA by Hdac2 ASO1 is long-lasting in primary neurons like was observed in the brain in vivo, we tested Hdac2 mRNA expression 14 days after rinsing and washing out the ASOs, and saw significant reduction persisting after the washout (Fig. 2D ).
Global transcription changes induced by Hdac2 ASO1 in vivo
Because HDAC2 is a regulator of histone acetylation, chronic reduction of HDAC2 protein is expected to cause changes to the transcriptome. Looking at the ~800 significantly changed genes in RNA-seq between 2 to 8 weeks, when animals had significantly enhanced memory in OLM ( Fig. 1F ), in the cortex and hippocampus revealed subgroups of genes with expression changes. In both regions, Hdac2 ASO1 significantly altered the expression of a small set of genes with immune functions and genes with involvement in ERK signaling. Many of these "immune" genes also have known roles in regulating memory (38). Other subgroups of genes that are identified in the cortex (Fig. 3A , blue cluster and red cluster, Table S2 ) are involved in cell adhesion, transcription, neuron projections, synapse organization, and myelination. The red cluster in Fig. 3B , represents a set of genes altered in the hippocampus involved in glucuronidation and flavonoid biosynthesis (Table S3 ).
ASO regulation of a putative Hdac2 extra-coding RNA
Previous work has demonstrated the existence of extra-coding RNAs (ecRNA) generated from many neuronal protein-coding genes, which promote their transcription (Di Ruscio et al. 2013; Savell et al. 2016 ).
These RNAs are sense transcripts that are unspliced and transcribe over mRNA sequences and prevent repression of their gene of origin. ecRNAs begin transcription upstream of the transcription start site (TSS), and terminatedownstream of the transcription end site (TES) of the gene they regulate. Since ecRNAs contain all of the sequences within the mRNA they control, our Hdac2 mRNA-targeting ASOs have target sequences matching both mRNA and ecRNA. We know from previous work that Fos has an ecRNA regulating its expression, and targeting the ecRNA of Fos with an ASO designed against a region downstream of the TES of Fos can reduce Fos mRNA level . We likewise found that Fos ecRNA ASOs reduce Fos mRNA transcript levels (Supplemental Fig. S3A ). Moreover, we found that a Fos mRNA-targeting ASO downregulates the expression of Fos ecRNA as well (Supplemental Fig. S3B ). This led us to investigate whether our Hdac2 mRNAtargeting ASOs also inhibit an Hdac2 ecRNA.
We first looked for evidence in previously published RNA-seq datasets that the ecRNA is generated from the Hdac2 gene in primary neuronal cultures of mice and rats. We used an RNA-seq library that detected lowly expressed and transient RNAs (Kim et al. 2010) , and a dataset that identified ecRNAs in rat primary neurons. The second dataset has polyadenylated transcripts separated from non-polyadenylated transcripts to better identify the non-polyadenylated ecRNAs . Reads in regions upstream of the TSS, in introns, and extending beyond the 3'UTR of Hdac2, consistent with the presence of an Hdac2 ecRNA, are seen in primary neurons of mice and rats ( Fig. 4A ). Furthermore, these Hdac2 ecRNA reads are predominantly present in the nonpolyadenylated fraction (Fig. 4A , PolyA-tracks). These findings suggest an Hdac2 ecRNA is generated. Because ASO1 and ASO2 target sequence is present in the mRNA, pre-mRNA, and ecRNA ( Fig. 4B) , we wanted to test if these ASOs repress the ecRNA as well as the mRNA. We found that in primary cortical neurons, ecRNA expression was reduced by both Hdac2 ASO1 and ASO2 (Fig. 4C) , demonstrating that Hdac2 mRNA-targeting ASOs are also capable of down-regulating the expression levels of the Hdac2 ecRNA. Likewise, targeting the ecRNA with the ecRNA-specific ASO reduced significantly not only the ecRNA (Fig. 4D, right) , but the Hdac2 mRNA level as well (Fig. 4D, left) . From these data, we conclude that the two transcribed products of the Hdac2 gene, the mRNA and the ecRNA, are both efficiently downregulated by ASOs, and solely targeting the ecRNA is sufficient to elicit mRNA knockdown.
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Hdac2 ASO1 causes no detectable change to DNA methylation at Hdac2 gene ecRNAs are reported to interact with DNA methyltransferases (DNMT), and prevent DNA methylation to maintain transcriptional accessibility (Di Ruscio et al. 2013; Savell et al. 2016 ). These prior studies show DNMT1 and DNMT3a are suppressed by ecRNA binding. Contrary to these models, we find that DNMT inhibitors 5azacitidine (5-Aza) and RG108, which target both DNMT1 and DNMT3a isoforms, do not antagonize the repression of Hdac2 mRNA by Hdac2 ASO1 (Supplemental Fig. S3C ). In addition, RG108 does not overcome the suppression of Fos mRNA and Fos ecRNA by Fos ecRNA ASOs (Supplemental Figs. S3D and S3E ), suggesting ASO-mediated repression of Fos is not DNA methylation-dependent either. Furthermore, direct measures of DNA methylation across the Hdac2 gene after treatment with Hdac2 ASO1 measured by MeDIP-qPCR also do not reveal any DNA methylation changes (Supplemental Fig. S3F ).
Direct transcriptional suppression by ASOs
Since ecRNAs are reported to regulate transcriptional accessibility, we tested the hypothesis that ASOs trigger transcriptional suppression of Hdac2 mRNA production. To determine if ASO1 and ASO2 prevent Hdac2 pre-mRNA production, we conducted nuclear run-on (NRO) experiments to quantify nascent Hdac2 transcripts.
During NRO, newly synthesized transcripts are purified by immunoprecipitation (IP). The IP method we optimized was able to isolate BrU-labeled RNA (+ samples), while washing away unlabeled RNA (-samples) with very low background signal (Fig. 5A ). The level of Hdac2 pre-mRNA in the immunoprecipitated nascent RNA fraction was measured by RT-qPCR. We observed that Hdac2 ASO1 treatment results in a significant reduction of transcription towards the 3' end of the Hdac2 gene in the 3'UTR in primary neurons (Fig. 5B ).
Hdac2 ASO2, although it targets a different exon, repressed Hdac2 transcription in a similar pattern to ASO1 in dN2a cells (Fig. 5C ). Interestingly, transcription near the 3', but not the 5', end of the Hdac2 gene was impeded in the NRO assay, which suggests that the elongation, but not the initiation, of transcription is blocked by Hdac2
ASOs. Hdac2 ASO1 elicited repression across all exons relative to SCR ASO in our sequencing of mature mRNA transcripts (Supplemental Fig. S4A ), suggesting this pattern of repression is a unique feature of nascent RNAs.
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HDACs have been implicated in transcriptional suppression as well as activation Greer et al. 2015) , so we tested if the changes we observed in the NRO experiment were an indirect effect of blocking HDAC activity using two broad-spectrum HDAC inhibitors, sodium butyrate (NaBu) and Suberoylanilide Hydroxamic Acid (SAHA). There was no repression of Hdac1 or Hdac2 transcript levels ( Supplemental Fig. S4B ), and Hdac2 transcription in NRO assays was not blocked by NaBu (Supplemental Fig. S4C ). Treatment of the cells with SAHA also did not reduce Hdac2 transcript levels, but actually increased Hdac1 and Hdac2 mRNA expression (Supplemental Fig. S4D ). Therefore, we conclude that Hdac2 ASOs directly reduce the transcription of their target gene irrespective of any epigenetic changes resulting from inhibition of deacetylation.
Based on the NRO assay, we predicted that RNA Pol II might be stalled near the promoter of the Hdac2 gene, preventing production of full-length transcripts. Therefore, we tested if Hdac2 mRNA expression is regulated by transcriptional pause release since not all genes are under the control of this mechanism of transcriptional regulation Zocchi et al. 2018) . Positive transcription elongation factor b (P-TEFb) is an important regulator of transcriptional pausing, and it is inhibited by the small molecule inhibitor Flavopiridol (FLAVO) (Chao and Price 2001) . In primary neuronal cultures and dN2a, FLAVO inhibits Hdac2 mRNA expression (Supplemental Fig. S4E ), so we conclude that RNA Pol II pausing is an important regulatory step in Hdac2 mRNA expression levels. Next, we looked to see if RNA Pol II is stalled at the promoter after Hdac2 ASO1 treatment. Since in the NRO experiments, the decrease in transcripts occurred downstream of Hdac2 intron 1, we looked for an accumulation of the initiated form of RNA Pol II (RNA Pol II phosphorylated at serine 5 of the C-terminal domain repeat region; RNA Pol II-pS5) (Komarnitsky et al. 2000; Phatnani and Greenleaf 2006) at intron 1 of the Hdac2 gene using ChIP-qPCR. Indeed, we found more binding of this active form of RNA Pol II at this pause site in the Hdac2 gene (Fig. 5D ), indicating that Hdac2 ASO1 leads to a pause in transcription near intron 1 of the Hdac2 gene.
DISCUSSION
Our studies indicate that Hdac2 ASOs provide a powerful avenue to generate long-lasting beneficial changes in epigenomic organization in the central nervous system. Specifically blocking Hdac2 expression with 15 this high precision compound leads to cognitive enhancement in WT mice, and prior studies suggest specific targeting of Hdac2 could be beneficial for treatment of autism (Kennedy et al. 2016 ) and Alzheimer's disease (Graff et al. 2012) .
We identified changes in the expression of many genes implicated in memory formation. For example, we see altered expression of genes associated with ERK signaling in the hippocampus and cortex, which has an important role in learning and memory. This signaling pathway is necessary for long-term potentiation of synaptic activity (Peng et al. 2010) . Additionally, we saw alterations in genes first identified as performing immune functions in peripheral tissues, but are also known to promote cognition (Nelson et al. 2013; Ru and Liu 2018) and synaptic plasticity (O'Brien et al. 1999; Golan et al. 2004; Stevens et al. 2007; Fuerst et al. 2008 ). Examples of immune-related factors with connections to memory we see changed by Hdac2 ASO1 in our datasets include Down syndrome cell adhesion molecule (DSCAM) proteins, pentraxins, tumor necrosis factor alpha, the complement system, and MHCII. Hdac2 regulates neuronal spine density, and the HDAC2 protein binds to the promoters of genes involved in synapse formation and plasticity (Guan et al. 2009 ). Accordingly, we identified that the Hdac2 ASO affects the expression of genes involved with cell adhesion and synapse formation in the cortex. We also found a subgroup of genes involved in flavonoid regulation in the hippocampus affected by Hdac2 ASO1 treatment. Importantly, flavonoids are now being studied with regards to their role in cognitive enhancement and regulation of inflammation (Bakoyiannis et al. 2019 ), suggesting there may be a link between the action of these compounds and Hdac2.
Hdac2 ASOs achieve their knockdown by preventing RNA Pol II elongation (Fig. 6 ). This transcriptional inactivation may explain the long-term effects of a single application of ASO, and is through an ecRNAdependent, DNA methylation-independent mechanism. Peptide nucleic acids (PNAs) that base pair with DNA, but have a peptide backbone, have been designed to target gene promoters and prevent RNA Pol II transcription through steric hindrance of transcription factor binding (Wang and Xu 2004) . Our data demonstrate that ASOs also act on transcription even if they are designed to target sequences far downstream of the promoter. It will be of interest to discriminate whether ASOs act like PNAs in blocking the binding of transcriptional regulators. ASOs employ several mechanisms to modulate RNA stability, splicing, and translation (DeVos and Miller 2013). Our study reveals a yet another mechanism of directly blocking transcriptional progression across the gene which enables ASOs modulate mRNA generation. ASOs elicit targeted mRNA reduction that is potent and long lasting without altering the underlying gene sequence, which makes them more attractive than other gene therapy approaches, like CRISPR (Gaj et al. 2013) , in certain contexts. This is because the transcriptional changes induced by ASOs are extremely specific, and enduring, but not permanent or damaging to genomic sequences.
METHODS
ASOs
Hdac2 ASO1 (5′-CToCoAoCTTTTCGAGGTToCoCTA-3′), Hdac2 ASO2 (5′-AToGoCoA GTTTGAAGTCToGoGTC-3′), Hdac2 ecRNA ASO (5′-CCoCoAoAATCACCTGTTCoToGAA-3′), and nontargeting scrambled (SCR) ASO (5′-GToToToTCAAATACACCToToCAT-3′) were generated by IONIS using the phosphorothioate and 2′-MOE modified ASO platform. Fos ASOs (Fos mRNA ASO (5'-UCUGUCAGCTCCCTCCUCCG-3'), Fos ecRNA ASO1 (5'-AGAUUGGCTGCTTGGUGGGU-3'), Fos ecRNA ASO2 (5'-ACUAGCGTGTCCTCTGAGUGA-3'), and non-targeting SCR ASO (5'-GUUUUCAAATACACCUUCAU-3')) were ordered from IDT. Sequences are designed for targeting mouse transcripts. Underlined residues are deoxynucleosides, and all others are 2´-O-methoxyethyl (2'-MOE) nucleosides. All linkages are phosphorothioate except those indicated by "o" between residues, which are phosphodiester.
Cell culture
Primary cortical neuron cultures were made from P0 mice. Dissected cortices were treated with papain supplemented with cysteine, and triturated to dissociate neurons. Cells were passed through a 70 μ m filter (Falcon), and grown in neurobasal complete media (neurobasal with 1x B27 supplement, 1mM sodium pyruvate, 1mM HEPES, 100U/mL penicillin, 100μg/mL streptomycin, and 0.5mM L-glutamine). Cells were treated overnight with FdU to kill dividing cells on day in vitro (DIV) 3, and 10μM ASO was applied on DIV 5. For washout experiments, neurons were treated 2 days with 10μM ASO. Cells were rinsed with complete neurobasal media, left a few minutes, and media was replaced again. ½ media changes were done every 2 to 3 days for all primary culture experiments. New media for changes did not contain ASO.
Neuro2a (N2a) cells were obtained from ATCC and grown according to recommended conditions. For long treatments plates were coated in poly-L-lysine. Cells attached overnight, and media was changed to differentiation media (DMEM with L-glutamine without glucose, 10mM galactose, 100U/mL penicillin, 100μg/mL streptomycin, and 1x N2 supplement) to make differentiated N2a (dN2a). After 4 days, half the media was changed and supplemented with complete neurobasal media at a ratio of 1:400 neurobasal to differentiation media. Half media changes were done as needed. Replacement media contained drug at the same concentration as the initial treatment.
For Fos ecRNA experiments, N2a were transfected with GenMute reagent according the manufacturer's specifications with ASO at a final concentration of 60nM. Media was changed to differentiation media 5 hours after transfection, and 2 days later changed to neurobasal media. RNA was extracted the following morning.
Mice
Male B6129S F1 hybrid mice at 2 months of age were acquired from The Jackson Laboratory. All procedures were performed with Institutional Animal Care and Use Committee (IACUC)-approved protocols and conducted in full compliance with the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
In vivo ASO administration
ASOs were injected by unilateral ICV bolus injection of 300 μ g. Mice were anaesthetized with 2% isoflurane and secured in a stereotaxic frame (David Kopf Instruments). ASOs were diluted to 60 
Targeted gene expression analysis
For mouse tissue samples, total RNA and DNA was extracted with AllPrep® DNA/RNA/miRNA kit (Qiagen).
RNA was extracted from the right hemisphere of the brain. Total mRNA was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad). For culture samples the RNeasy plus kit (QIAGEN) and SuperScript VILO (Invitrogen) was used according to manufacturer's instructions. qPCR was performed with the CFX96 Optical Reaction Module (Bio-Rad) using SYBR green (Bio-Rad). Relative gene expression from in vivo samples was determined using the ΔΔCt method (Livak and Schmittgen 2001) and normalized to a housekeeping gene. qPCR primer sequences are listed in Table S1 .
Western blots
Tissue from the left hemisphere of the brain was homogenized in RIPA buffer. Protein samples were run on 4-20% TGX Gels (Bio-Rad) and then transferred to PVDF membranes (Millipore) using standard protocols. Primary antibodies were: HDAC2 (Abcam ab12169) and actin (Abcam ab3280). Secondary antibodies were goat anti mouse IR 680 (LiCor #926-68020) and goat anti mouse IR 800 (LiCor #926-32210). Membranes were imaged on the LiCor Odyssey fluorescence imaging system.
Object location memory test (OLM)
Mice were habituated to an opaque polyurethane open box (10 × 10 × 12 in. (x, y, z)) containing autoclaved bedding with one black line spatial cue for 3 days (5 min. per day) prior to training. Mice were trained for 10 min.
with two 50 ml beakers in a particular location. 24 hr. after training, one beaker was moved to a novel location and the mice were tested for 5 min. Videos were scored by hand and blinded to subject identity. Object interaction was scored as previously described (Haettig et al. 2011) . buffer for 10 min., blocking buffer was added, and beads rotated another 30 min. at RT. After blocking, beads were washed 2 times with binding buffer. The blocked bead mixture was combined with RNA sample, and put on a rotating stand for 30 min. at RT. After binding, beads were washed twice for 2 min. in BrU binding buffer, once in low salt buffer, once in high salt buffer and twice in TET buffer. Buffer compositions were previously published ). On the final TET wash, beads were moved to a new tube, TET was removed, and TRIzol was used to elute and purify RNA as previously described . Three rounds of immunoprecipitation were conducted on each sample. Purified RNA samples were heated at 65°C for 5 min. then placed on ice at least for 2 min. prior to IP or reverse transcription reaction. Multiscribe reverse transcriptase was used to make cDNA according to manufacturer's recommendations.
For the non-specific binding check, NRO samples made with UTP were run in parallel to samples made with BrUTP. The elution after the third round of BrdU immunoprecipitation was run on a bioanalyzer Eukaryote Total RNA Pico Series II chip according the manufacturer's instructions. Signal intensity is normalized across all samples in the gel-like output image.
Total RNA-seq Total RNA-seq libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero Gold (Illumina) according to manufacturer's instructions. 1µg of RNA was used as starting material and amplified with 12 PCR cycles. Library size distribution was checked with an Agilent 2100 Bioanalyzer and quantity was determined using qPCR. Libraries were sequenced on an Illumina HiSeq 2500 using a 50-cycle rapid run kit or an Illumina NextSeq instrument using a 75-cycle high throughput kit. Reads were aligned to the GRCm38.p3 mouse genome and transcriptome using TopHat (Trapnell et al. 2009 ) and differential expression tests were performed using featureCounts (Liao et al. 2014 ) and edgeR (Robinson et al. 2010; McCarthy et al. 2012) Heatmaps were generated with gplots package in R.
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Statistics ANOVA and Student's t tests were conducted in GraphPad Prism version 8 with indicated post-hoc tests.
DATA ACCESS
All raw sequencing data generated in this study have been submitted to the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE124726. All relevant data from this study are available on request from the corresponding authors (C.B.G. or T.P.M.).
